Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
1999 4
2000 1
2001 3
2002 2
2004 3
2005 2
2006 2
2007 1
2008 2
2009 2
2010 2
2012 2
2013 2
2014 2
2015 1
2017 2
2018 4
2019 2
2020 5
2021 4
2022 10
2023 15
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

69 results

Results by year

Filters applied: . Clear all
Page 1
USP51 facilitates colorectal cancer stemness and chemoresistance by forming a positive feed-forward loop with HIF1A.
Mu M, Zhang Q, Li J, Zhao C, Li X, Chen Z, Sun X, Yu J. Mu M, et al. Cell Death Differ. 2023 Nov;30(11):2393-2407. doi: 10.1038/s41418-023-01228-8. Epub 2023 Oct 10. Cell Death Differ. 2023. PMID: 37816999
In the current study, we have shown that USP51 promotes colorectal cancer stemness and chemoresistance, and high expression of USP51 predicts survival disadvantage in colorectal cancer patients. ...Thus, USP51 and HIF1A form a positive feedback loop. Further, we fou …
In the current study, we have shown that USP51 promotes colorectal cancer stemness and chemoresistance, and high expression of USP51 …
What's new in the WHO 2022 classification of kidney tumours?
Alaghehbandan R, Siadat F, Trpkov K. Alaghehbandan R, et al. Pathologica. 2022 Feb;115(1):8-22. doi: 10.32074/1591-951X-818. Epub 2023 Jan 16. Pathologica. 2022. PMID: 36645398 Free PMC article. Review.
Novel entities included in the WHO 2022 classification are eosinophilic solid and cystic renal cell carcinoma (ESC RCC), anaplastic lymphoma kinase (ALK)-rearranged RCC and ELOC (formerly TCEB1)-mutated RCC. The category of "other renal tumours" includes a group of diverse …
Novel entities included in the WHO 2022 classification are eosinophilic solid and cystic renal cell carcinoma (ESC RCC), anaplastic lymphoma …
The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs-Part A: Renal, Penile, and Testicular Tumours.
Moch H, Amin MB, Berney DM, Compérat EM, Gill AJ, Hartmann A, Menon S, Raspollini MR, Rubin MA, Srigley JR, Hoon Tan P, Tickoo SK, Tsuzuki T, Turajlic S, Cree I, Netto GJ. Moch H, et al. Eur Urol. 2022 Nov;82(5):458-468. doi: 10.1016/j.eururo.2022.06.016. Epub 2022 Jul 16. Eur Urol. 2022. PMID: 35853783 Free article. Review.
Such novel molecularly defined epithelial renal tumours include SMARCB1-deficient medullary renal cell carcinoma (RCC), TFEB-altered RCC, Alk-rearranged RCC, and ELOC-mutated RCC. Eosinophilic solid and cystic RCC is a novel morphologically defined RCC entity. ...
Such novel molecularly defined epithelial renal tumours include SMARCB1-deficient medullary renal cell carcinoma (RCC), TFEB-altered RCC, Al …
Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA, Rutishauser D, Sobottka B, Schraml P, Beerenwinkel N, Moch H. Batavia AA, et al. Mod Pathol. 2023 Aug;36(8):100194. doi: 10.1016/j.modpat.2023.100194. Epub 2023 Apr 23. Mod Pathol. 2023. PMID: 37088333 Free article.
Biallelic ELOC and biallelic VHL aberrations were mutually exclusive; however, 2 ELOC-mutated RCCs showed monoallelic VHL alterations. Furthermore, no mutations in TSC1, TSC2, or mTOR were identified in ELOC-mutated RCC with biallelic ELOC inactivation …
Biallelic ELOC and biallelic VHL aberrations were mutually exclusive; however, 2 ELOC-mutated RCCs showed monoallelic VHL alte …
Clinico-pathological implications of the 2022 WHO Renal Cell Carcinoma classification.
Rizzo M, Caliò A, Brunelli M, Pezzicoli G, Ganini C, Martignoni G, Camillo P. Rizzo M, et al. Cancer Treat Rev. 2023 May;116:102558. doi: 10.1016/j.ctrv.2023.102558. Epub 2023 Apr 9. Cancer Treat Rev. 2023. PMID: 37060647 Review.
While the most common histotype remains almost untouched, some of the main novelties concerns papillary RCC and oncocytic neoplasms. The main change is the introduction of a new category of molecularly-defined RCC, which includes TFE3-rearranged RCC, TFEB-rearranged, and T …
While the most common histotype remains almost untouched, some of the main novelties concerns papillary RCC and oncocytic neoplasms. …
Elongin C (ELOC/TCEB1)-associated von Hippel-Lindau disease.
Andreou A, Yngvadottir B, Bassaganyas L, Clark G, Martin E, Whitworth J, Cornish AJ; Genomics England Research Consortium; Houlston RS, Rich P, Egan C, Hodgson SV, Warren AY, Snape K, Maher ER. Andreou A, et al. Hum Mol Genet. 2022 Aug 23;31(16):2728-2737. doi: 10.1093/hmg/ddac066. Hum Mol Genet. 2022. PMID: 35323939 Free PMC article.
ELOC encodes elongin C, a key component [C] of the VCB-CR complex. ...These findings are consistent with pathogenic ELOC variants being a novel cause for VHL disease and suggest that genetic testing for ELOC variants should be performed in individuals with su …
ELOC encodes elongin C, a key component [C] of the VCB-CR complex. ...These findings are consistent with pathogenic ELOC varia …
The 2022 revision of the World Health Organization classification of tumors of the urinary system and male genital organs: advances and challenges.
Mohanty SK, Lobo A, Cheng L. Mohanty SK, et al. Hum Pathol. 2023 Jun;136:123-143. doi: 10.1016/j.humpath.2022.08.006. Epub 2022 Sep 6. Hum Pathol. 2023. PMID: 36084769 Review.
Major nomenclature changes include replacement of histologic "variants" by "subtypes," "clear cell papillary renal cell carcinoma" to "clear cell renal cell tumor," "TCEB1-mutated RCC" to "ELOC-mutated RCC," "hereditary leiomyomatosis and renal cell carcinoma" to "fumarate …
Major nomenclature changes include replacement of histologic "variants" by "subtypes," "clear cell papillary renal cell carcinoma" to "clear …
Integrated molecular analysis of clear-cell renal cell carcinoma.
Sato Y, Yoshizato T, Shiraishi Y, Maekawa S, Okuno Y, Kamura T, Shimamura T, Sato-Otsubo A, Nagae G, Suzuki H, Nagata Y, Yoshida K, Kon A, Suzuki Y, Chiba K, Tanaka H, Niida A, Fujimoto A, Tsunoda T, Morikawa T, Maeda D, Kume H, Sugano S, Fukayama M, Aburatani H, Sanada M, Miyano S, Homma Y, Ogawa S. Sato Y, et al. Nat Genet. 2013 Aug;45(8):860-7. doi: 10.1038/ng.2699. Epub 2013 Jun 24. Nat Genet. 2013. PMID: 23797736
Clear-cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer and its molecular pathogenesis is incompletely understood. ...
Clear-cell renal cell carcinoma (ccRCC) is the most prevalent kidney cancer and its molecular pathogenesis is incompletely understood …
Genomic alterations and diagnosis of renal cancer.
Zhang X, Bolck HA, Rupp NJ, Moch H. Zhang X, et al. Virchows Arch. 2024 Feb;484(2):323-337. doi: 10.1007/s00428-023-03700-9. Epub 2023 Nov 24. Virchows Arch. 2024. PMID: 37999735 Free PMC article. Review.
This review aims to provide an overview of the most important molecular alterations in renal cancer, with a specific focus on the diagnostic value of characteristic genomic aberrations, their chromosomal localization, and associations with renal tumor subtypes. It may not …
This review aims to provide an overview of the most important molecular alterations in renal cancer, with a specific focus on the dia …
Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
Wang Y, Zhao P, Wang L, Wang J, Ji X, Li Y, Shi H, Li Y, Zhang W, Jiang Y. Wang Y, et al. Pathol Res Pract. 2022 Jul;235:153960. doi: 10.1016/j.prp.2022.153960. Epub 2022 May 27. Pathol Res Pract. 2022. PMID: 35653922
RESULTS: The 4 patients with ELOC(TCEB1) mutations were all males and aged between 57 and 64 years (median age: 59 years old). ...CONCLUSION: ELOC(TCEB1)-mutant renal cell carcinoma is a rare type of renal cell carcinoma, which tends to occur in middle-aged and elde …
RESULTS: The 4 patients with ELOC(TCEB1) mutations were all males and aged between 57 and 64 years (median age: 59 years old). ...CON …
69 results